Login to Your Account



Deal Could Reach €150M

Novexel Receives €75M Up Front for Beta Lactamase Inhibitor

By James Etheridge


Wednesday, January 23, 2008

Novexel SA and Forest Laboratories Holdings Ltd., a wholly owned subsidiary of Forest Laboratories Inc. signed an agreement allowing the U.S. company to develop, manufacture and commercialize Novexel's novel intravenous beta lactamase inhibitor, NXL104, in combination with Forest's ceftaroline. (BioWorld International)

 

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription